Published in Acta Psychiatr Scand on October 01, 1992
Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics (2014) 0.94
Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics. Neuropsychiatr Dis Treat (2014) 0.75
Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci (1998) 4.76
Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry (1989) 2.41
Basal cortisol levels and cognitive deficits in human aging. J Neurosci (1994) 1.97
Stress-induced declarative memory impairment in healthy elderly subjects: relationship to cortisol reactivity. J Clin Endocrinol Metab (1997) 1.56
Increased cortisol levels and impaired cognition in human aging: implication for depression and dementia in later life. Rev Neurosci (1999) 1.47
Factors in the development of severe forms of tardive dyskinesia. Am J Psychiatry (1990) 1.39
Longitudinal study of basal cortisol levels in healthy elderly subjects: evidence for subgroups. Neurobiol Aging (1996) 1.07
A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Acta Psychiatr Scand Suppl (1990) 1.05
Late-onset bipolar disorder. Psychiatr Clin North Am (1988) 0.99
Individual differences in hypothalamic-pituitary-adrenal activity in later life and hippocampal aging. Exp Gerontol (1995) 0.97
Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. Neuroscience (1986) 0.94
Apomorphine-induced penile tumescence in impotent patients--preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry (1987) 0.94
A five-year outcome of discharged chronic psychiatric patients. Can Psychiatr Assoc J (1972) 0.94
Apomorphine: clinical studies on erectile impotence and yawning. Prog Neuropsychopharmacol Biol Psychiatry (1989) 0.94
Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull (1992) 0.93
Diazepam in high doses is effective in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (1982) 0.93
Circadian rhythm of plasma melatonin in endogenous depression. Prog Neuropsychopharmacol Biol Psychiatry (1984) 0.89
Alzheimer's disease may not be a spirochetosis. Neuroreport (1999) 0.89
Differential effect of unilateral and bilateral ECT. Am J Psychiatry (1970) 0.88
The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol (1987) 0.87
Reduced lumbar CSF somatostatin levels in Alzheimer's disease. Life Sci (1982) 0.87
Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets. Biol Psychiatry (1994) 0.86
Effect of sleep deprivation on dopamine receptor function in normal subjects. J Neural Transm (1981) 0.86
The Major Depression Rating Scale (MDS). Inter-rater reliability and validity across different settings in randomized moclobemide trials. Danish University Antidepressant Group. J Affect Disord (1997) 0.84
Comparative potencies of calcium channel antagonists and antischizophrenic drugs on central and peripheral calcium channel binding sites. J Pharm Pharmacol (1985) 0.83
High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients. Psychopharmacology (Berl) (1983) 0.81
Effect of sulpiride, an atypical neuroleptic, on apomorphine-induced growth hormone secretion. Brain Res Bull (1982) 0.81
Clinical and neuroendocrine studies with cholecystokinin peptides. Ann N Y Acad Sci (1985) 0.80
The Kleine-Levine syndrome--a variant? J Clin Psychiatry (1978) 0.80
Baclofen in the treatment of tardive dyskinesia. Am J Psychiatry (1978) 0.80
A post-mortem comparison of the cortical cholinergic system in Alzheimer's disease and Pick's disease. J Neurol Sci (1983) 0.80
Outcome variables in presymptomatic individuals at higher risk of developing Alzheimer disease. Alzheimer Dis Assoc Disord (1996) 0.80
Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure. J Neurochem (1986) 0.79
Glucocorticoid receptor gene expression is unaltered in hippocampal neurons in Alzheimer's disease. Brain Res Mol Brain Res (1993) 0.79
CSF acetylcholinesterase in dementia and in sequential samples of lumbar CSF. Neurobiol Aging (1984) 0.79
Effect of lithium on hypothalamic-pituitary dopaminergic function. Acta Psychiatr Scand (1978) 0.79
Clinical relevance of serum nortriptyline and 10-hydroxy-nortriptyline measurements in the depressed elderly: a multicenter pharmacokinetic and pharmacodynamic study. Neuropsychopharmacology (1996) 0.78
Lack of cholinergic deficit in the neocortex in Pick's disease. Prog Neuropsychopharmacol Biol Psychiatry (1983) 0.78
Parkinsonism induced by high doses of diazepam. Biol Psychiatry (1985) 0.78
Levomepromazine receptor binding profile in human brain--implications for treatment-resistant schizophrenia. Acta Psychiatr Scand (1993) 0.78
Plasma melatonin--an index of brain aging in humans? Biol Psychiatry (1986) 0.78
The effect of Yohimbine, an alpha2 adrenergic receptor antagonist, on the growth hormone response to apomorphine in normal subjects. J Psychiatry Neurosci (1996) 0.77
Effect of normal aging on the prolactin response to graded doses of sulpiride and to arginine. Prog Neuropsychopharmacol Biol Psychiatry (1985) 0.77
Neuroendocrine evaluation of CCK-peptides on dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry (1983) 0.77
Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy. J Neurol Neurosurg Psychiatry (1976) 0.77
Normalization of platelet [3H]imipramine binding in depressed patients during remission. Eur J Pharmacol (1982) 0.77
Effect of domperidone on apomorphine-induced growth hormone secretion in normal men. J Neural Transm (1982) 0.77
Comparative autoradiographic distribution of calcium channel antagonist binding sites for 1,4-dihydropyridine and phenylalkylamine in rat, guinea pig and human brain. Prog Neuropsychopharmacol Biol Psychiatry (1985) 0.77
Cholecystokinin appears to have antipsychotic properties. Prog Neuropsychopharmacol Biol Psychiatry (1982) 0.77
Cholecystokinin and schizophrenia. Prog Brain Res (1986) 0.77
Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. Can J Neurol Sci (1986) 0.77
Stereospecificity of the dopamine receptor mediating the growth hormone response to apomorphine in man. Short communication. J Neural Transm Gen Sect (1991) 0.77
Is levomepromazine a useful drug in treatment-resistant schizophrenia? Acta Psychiatr Scand (1992) 0.77
A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord (1994) 0.77
Effect of some peptides on dopaminergic function in man. J Neural Transm Suppl (1990) 0.77
Buspirone: a potential atypical neuroleptic. Life Sci (1983) 0.77
Platelet 3H-imipramine binding and red blood cell choline in affective disorders: indications of heterogeneous pathogenesis. Biol Psychiatry (1983) 0.77
beta-Endorphin and naloxone in psychiatric patients: clinical and biological effects. Am J Psychiatry (1979) 0.77
Clonidine-induced growth hormone secretion in chronic schizophrenia. Acta Psychiatr Scand (1983) 0.77
Effect of imipramine on the circadian rhythm of plasma melatonin in unipolar depression. Chronobiol Int (1986) 0.76
Localization of cholecystokinin binding sites in canine brain using quantitative autoradiography. Prog Neuropsychopharmacol Biol Psychiatry (1991) 0.76
A double blind comparison of alprazolam and amitriptyline hydrochloride in the treatment of nonpsychotic depression. Can J Psychiatry (1988) 0.76
Cholecystokinin peptides, dopamine and schizophrenia--a review. Prog Neuropsychopharmacol Biol Psychiatry (1985) 0.76
Antagonists of excitatory amino acids and cyclic guanosine monophosphate in cerebellum. Neuropharmacology (1982) 0.76
Cardiovascular, neuroendocrine, and monoaminergic responses to psychological stressors: possible differences between remitted panic disorder patients and healthy controls. Biol Psychiatry (1996) 0.76
Platelet 3H-imipramine binding distinguishes depression from Alzheimer dementia. Life Sci (1985) 0.76
Imipramine treatment differentially affects platelet 3H-imipramine binding and serotonin uptake in depressed patients. Life Sci (1985) 0.76
Lack of association between [3H]imipramine binding sites and uptake of serotonin in control, depressed and schizophrenic patients. Neuropharmacology (1983) 0.76
Differential actions of classical and atypical neuroleptics on mouse nigrostriatal neurons. Prog Neuropsychopharmacol Biol Psychiatry (1983) 0.76
Nucleus basalis neuronal loss and neuritic plaques in advanced Alzheimer's disease. Can J Physiol Pharmacol (1986) 0.76
An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study. J Psychiatry Neurosci (1995) 0.76
The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline. Biol Psychiatry (1997) 0.76
Unique [3H]tryptamine binding sites in rat brain: distribution and pharmacology. Arch Int Pharmacodyn Ther (1984) 0.76
Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates. Clin Neuropharmacol (1997) 0.76
Verapamil in the treatment of chronic schizophrenia. Psychopharmacol Bull (1987) 0.76
Effect of hydrocortisone on basal and apomorphine-induced growth hormone secretion in normal subjects. Clin Invest Med (1988) 0.76
Characterization and possible role of growth factor and lymphokine receptors in the regulation of cholinergic function in the mammalian brain. Prog Clin Biol Res (1989) 0.76
Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia. Neuropsychobiology (1979) 0.75
Platelet imipramine binding in patients with panic disorder and major familial depression. J Psychiatr Res (1987) 0.75
Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. Clin Neuropharmacol (1993) 0.75
Efficacy and safety of brofaromine in depression: a Canadian multicenter placebo controlled trial and a review of comparative controlled studies. Clin Neuropharmacol (1992) 0.75
Dopamine and schizophrenia. A reappraisal in the light of clinical studies with clozapine. Can Psychiatr Assoc J (1977) 0.75
Differences in symptomatology and diagnostic profile in younger and elderly depressed inpatients. J Affect Disord (2001) 0.75
Visualization of growth factor receptor sites in rat forebrain. Synapse (1988) 0.75
Serotonin uptake in panic disorder and agoraphobia. Neuropsychopharmacology (1988) 0.75
The effect of electroconvulsive therapy on endorphins in depression. Biol Psychiatry (1988) 0.75
Striatal 3-methoxytyramine as an index of dopamine release effects of electrical stimulation. Neurosci Lett (1982) 0.75
Hypothalamic-pituitary dopaminergic function in hepatic failure in man. J Neural Transm (1982) 0.75
Effect of CCK-33 on prolactin and apomorphine-induced growth hormone secretion in man. Horm Metab Res (1983) 0.75
Growth hormone response to apomorphine, a dopamine receptor agonist, in normal aging and in dementia of the Alzheimer type. Neurobiol Aging (1989) 0.75
Gabaergic regulation of nigrostriatal neurons: coupling of benzodiazepine and GABA receptors. Prog Neuropsychopharmacol Biol Psychiatry (1982) 0.75
Care of chronic psychotics. Br Med J (1971) 0.75
Neurochemical and receptor theories of depression. Psychiatr J Univ Ott (1989) 0.75
Trazodone in the treatment of organic brain syndromes, with special reference to psychogeriatrics. Curr Ther Res Clin Exp (1973) 0.75
Drug-induced growth hormone and prolactin responses in schizophrenia research. Prog Neuropsychopharmacol Biol Psychiatry (1982) 0.75
Trazodone in the treatment of schizophrenias. Curr Ther Res Clin Exp (1973) 0.75
Effect of lithium and neuroleptic combination on lithium transport, blood pressure, and weight in bipolar patients. Biol Psychiatry (1989) 0.75
The effect of methyltestosterone on the growth hormone response to the dopamine receptor agonist, apomorphine. Prog Neuropsychopharmacol Biol Psychiatry (1991) 0.75
Transmembrane lithium distribution and hypertension in manic depressive patients. Prog Neuropsychopharmacol Biol Psychiatry (1989) 0.75
Reduced cortical choline acetyltransferase activity in Gerstmann-Sträussler syndrome. Prog Neuropsychopharmacol Biol Psychiatry (1982) 0.75